INTRODUCTION
With the increasing concerns related to the overdiagnosis and overtreatment of prostate cancer (PCa), the interest in conservative management approaches of active surveillance (AS) has been increasing rapidly. [1] [2] [3] Although questions still remain regarding its efficacy and safety, AS is currently included as a treatment option in the guidelines for the management of localized PCa published by the European Association of Urology, the American Urological Association, and the National Comprehensive Care Network. [4] [5] [6] Certainly, many of the published criteria used for the identification of men who are eligible for AS are based on Epstein criteria for clinically insignificant PCa (clinical stage ≤ T1, prostate specific antigen [PSA] density ≤ 0.15 ng ml −1 cm −3 , biopsy Gleason score ≤ 6, number of positive biopsy cores ≤ 2, and no core with > 50% involvement). 7 Today, various institutions apply different eligibility criteria for AS. [8] [9] [10] [11] When these criteria are compared, there may well be a clear trade-off between sensitivity and specificity for predicting insignificant PCa. Meanwhile, it remains to be determined whether the application of most conservative criteria is optimal. 12 The accurate identification of men with insignificant disease still remains a challenging goal.
The increased use of the PSA test along with lowering of the PSA thresholds for biopsy may have contributed to a higher proportion of men diagnosed with disease that is amenable to AS. It has been suggested that stricter criteria for AS may unnecessarily exclude potential candidates for AS. Accordingly, efforts to expand the criteria for AS have been reported. 13, 14 Despite the fact that AS was
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RESULTS

Characteristics of our subjects are listed in
Regarding the adverse pathologic features in group A and B, no significant difference in any adverse pathologic outcome was observed between groups A and patients of group B who had clinical stage > T1c (all P > 0.05) ( Table 2) . Compared with group A, group B patients with PSA density > 0.15 ng ml −1 cm −3 or biopsy Gleason score > 6 had significantly higher rates of 2 or more adverse pathologic features, including significant tumor (both P < 0.001). Comparing patients in group A with group B patients with PSA density of 0.15 ng ml −1 cm −3 to 0.20 ng ml
, a significant difference in the rate of ECE was observed (4.6% vs 13.8%, P = 0.003). Group B patients who had 3 or more positive biopsy cores did not show significantly higher risk of any adverse pathology compared with group A (all P > 0.05). Because the number of group B patients with > 50% core involvement was only 7, comparing adverse pathologic outcomes of these men and those of the group A was not deemed appropriate.
The results of multivariable logistic regression analysis of the associations between each of the 5 criteria for clinically insignificant PCa and adverse pathological features are shown in Table 3 . High PSA density was associated with ECE and significant tumor. In addition, high biopsy Gleason score was associated with high pathological Gleason score and significant tumor. In contrast, advanced clinical stage was not associated with any adverse pathologic features. Meanwhile, although men with 3 positive cores were not associated with any adverse pathology, those with 4 or more positive cores were shown to be associated with higher risk of ECE. Although higher percent core positivity was associated with higher risk of ECE, the number of patients with > 50% core positivity was too small as mentioned above.
Regarding postoperative BCR-free survival, group A and B demonstrated no significant difference during a mean follow-up period of 49.62 months (median 49) (log rank P = 0.418). When group B was sub-stratified according to the criterion for clinically insignificant PCa not met by each patient, 5 subgroups showed no significant differences in biochemical outcomes compared with a group A (log rank P = 0.080). Because the two variables of PSA density and biopsy Gleason score were the criteria that were most strongly associated with adverse pathologic features compared with the other 3 criteria for clinically insignificant PCa, we re-analyzed BCR-free survivals after stratifying patients by PSA density (<0.15, 0.15-0.18, 0.19-0.23, and > 0.23) and biopsy Gleason score (3 + 3, 3 + 4, 4 + 3, and ≥ 8). No significant differences in biochemical outcome were observed when patients were stratified according to PSA density (log rank, P = 0.578).
Comparison of the men with PSA density < 0.15 ng ml −1 cm −3 and those with PSA density of 0.15 ng ml −1 cm −3 to 0.20 ng ml −1 cm −3 revealed, no significant differences regarding biochemical outcome (log rank, P = 0.973). However, BCR-free survivals were significantly shorter for men with biopsy Gleason score 4 + 3 compared with those with 3 + 3 (log rank, P < 0.001). Meanwhile, no significant differences in biochemical outcome were observed between men with Gleason 3 + 4 and 3 + 3 tumors (log rank P = 0.603). Additionally, no significant differences in biochemical outcome were noted between group A and the men in group B stratified according to the number of positive cores (log rank P = 0.568).
DISCUSSION
By analyzing each criterion for predicting insignificant PCa, which also make up many different eligibility criteria for AS, we observed that biopsy Gleason score > 6 and PSA density > 0.15 ng ml −1 cm −3 were the most strongly associated with adverse pathologic features amongst potential candidates for AS. In contrast, higher (> T1c) clinical stage was not associated with adverse pathology in the potential candidates for AS. Meanwhile, the number of positive cores was shown to be less associated with adverse pathology than biopsy Gleason score and PSA density. Our results suggested that men with up to 3 positive cores who met all other criteria for clinically insignificant PCa could safely be enrolled onto an AS program. Due to the relatively smaller number of patients with higher percent core involvement, an appropriate evaluation of this criterion was not feasible in this study.
Previously Reese et al. 16 performed a study to determine the relative importance of the same AS eligibility criteria evaluated in our study. Analyzing men treated with RP between 1995 and 2012 who met 4 or more of the 5 criteria, they found that PSA density > 0. 15 12 In their series, Reese et al.
14 found that men with 3 positive biopsy cores and 50%-60% core involvement who met all other criteria are suitable candidates for AS. Although we could not perform adequate analysis on the criterion of percentage core involvement, men with 3 positive cores were also not associated with significantly higher risk of adverse pathology at RP or worse biochemical outcome compared with those with 1 or 2 positive cores in our study. The results of our study confirmed several findings from the study by Reese et al. On the other hand, there were notable differences in study design between the two studies. First, Reese et al. had to exclude more than half of the men included in their RP series upfront due to missing clinical data. Second, 12 or more biopsy cores were obtained in more than 85% of the patients in our study whereas only approximately 20% had biopsy with 12 or more cores in the Reese et al. 's study. Third, we used prostate volume measured via preoperative TRUS or magnetic resonance imaging to calculate the PSA density as is typically performed in actual clinical settings whereas prostate volume estimated from RP specimen weight was used to calculate the PSA density in the Reese et al. 's study. Despite the difference in the size of the patient cohort, we believe that our cohort, which is more contemporary, may be more appropriate for the proper evaluation of AS eligibility criteria, which are preoperative clinical variables that mostly biopsy-related. Currently, AS is still considered to be underused in western countries. Meanwhile, it is even less frequently employed in Asia. Except for only a few anecdotal cases, the number of patients formally enrolled in an AS program at our institution was low during the study period. In addition, radiotherapy was seldom recommended for low-risk PCa at our institution. Due to such circumstances, our subjects may be considered representative of almost all of the potential candidates for AS managed at our institution during the study period. As the number of men undergoing AS is increasing in western institutions, 18 the possibility of selection bias should be considered in the interpretation of contemporary RP series on potential candidates for AS reported from large, western institutions.
Among our subjects, only 172 of 1908 (approximately 9%) from total RP series would have been deemed suitable for AS if original Epstein criteria were used as the AS eligibility criteria at our institution during the study period. The fact that PSA testing is relatively less prevalent in Asia than in western countries may have, at least partly, contributed to such a low rate of favorable disease among our RP cohort. Meanwhile, if the criteria were expanded according to our findings, 50 men with clinical stage ≥ T2 and 29 men with 3 positive cores would have been additionally considered appropriate for AS (45.93% increase). Such a finding would certainly be clinically significant considering that these additional men would be spared of the morbidities from unnecessary radical treatments with the expansion of criteria.
Regarding the discrimination between biopsy Gleason score of 3 + 3 and 3 + 4, a significantly higher rate of adverse pathologic features at RP among our subjects with biopsy Gleason 3 + 4 tumor would support the exclusion of these men from AS programs. Meanwhile, others mentioned that select patients with Gleason 3 + 4 tumor can be considered for AS. Moreover, we observed no significant difference in BCR-free survivals between group A and those in group B with Gleason 3 + 4 tumor during a mean follow-up duration of approximately 50 months. Nevertheless, biochemical outcome may have been different with longer follow-ups. Because pathologic and biochemical outcomes can only be considered as surrogates for long-term outcomes (metastasis-free or disease-specific survival), we admit that inherent limitations would exist regarding the interpretations of our findings.
Recently, efforts have been made to integrate the state-of-the-art methods of genetic assays to identify appropriate candidates for AS. The cell cycle progression signature test (Prolaris) is a gene expression based assay that directly measures tumor growth capacity allowing the stratification of patients with localized PCa according to cancer aggressiveness. [19] [20] [21] This test combines the gene expression levels of 31 genes associated with cell cycle progression and 15 housekeeping genes into a cell cycle progression score that can be used to predict the risk of BCR, metastasis, and cancer-specific mortality. Similarly, a multi-gene, real-time polymerase chain reaction (RT-PCR) assay (Oncotype DX Assay) has been developed. 22 This assay includes 5 reference genes and 12 cancer genes representing distinct biological pathways with a known role in prostate tumorigenesis. Reference normalized expression of 12 cancer-related genes is used to calculate the so called Genomic Prostate Score which can be used to predict adverse pathologic features beyond conventional variables. Although still not widely adopted, it is hoped that new assays that utilizing molecular biomarkers would complement conventional clinical and pathological parameters to personalize the care of cancer patients. Meanwhile, regardless of the advancement in diagnostic tools, studies on the prediction of outcomes or the selection of candidates for AS can only be problematic until long-term follow-up data on AS become available.
Our study may be limited by its retrospective nature. Though many different versions of AS eligibility criteria are currently used, only items included in the Epstein criteria were evaluated in this study. Although the number of our subjects is relatively small compared with other similar series, it should be noted that we excluded men who underwent RP before 2006 to minimize the effect from the modifications of Gleason grading system introduced by the International Society of Urological Pathology in 2005. 23 Because our series is only based on men who underwent RP, our findings may not be representative of men who underwent other forms of treatment, such as radiotherapy. In addition, data on tumor volume from RP specimens were not available in our subjects.
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